Research
Hormonal
NN1706 lowers body weight & improves glycemic control in obese rodents and monkeys.
NN1706 may also be beneficial for weight management and glycemic control in animal models of obesity.
StrongSupportsmedium confidence
NN1706 lowers body weight & improves glycemic control in obese rodents and monkeys.
Why this rating
The claim is based on animal studies that are part of the research.
Source
A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans
Brian Finan et al. · Molecular Metabolism · 2025
DOI 10.1016/j.molmet.2025.102129
otherCited 13×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →